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OBJECTIVE—This study clariﬁed characteristics of interferon-associated type 1 diabetes.
RESEARCH DESIGN AND METHODS—Thestudycompared12patientswithinterferon-
associatedtype1diabeteswith128 patients with type 1Adiabeteswith respect toclinicalcharacter-
istics,andwith10patientswithoutdiabetesdespiteinterferontherapyand136normalcontrolswith
respect to HLA allele distributions.
RESULTS—Patientswith interferon-associated type 1diabetesretainedhigher levels of fasting
serum C peptide as well as GAD65 antibodies than those with type 1A diabetes until 2 to 4 years
afteronset.HLA-A*2402wasincreasedamongpatientswithinterferon-associatedtype1diabetes
comparedwiththosewithoutdiabetes,despiteinterferontherapy(oddsratio[OR]4.00[95%CI
1.09–17.26]). The haplotype of DRB1*1302-DQA1*0102-DQB1*0604 was increased in these
two groups combined compared with normal controls (OR 5.64 [95% CI 2.67–11.81]).
CONCLUSIONS—Interferon-associated type 1 diabetes is characterized clinically by high
titers of GAD65 antibodies and preserved b-cell function, and genetically by addition of HLA-
A*2402 to DRB1*1302-DQA1*0102-DQB1*0604.
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nterferon a is used to treat several dis-
eases, including chronic hepatitis C
(1), and rarely causes type 1 diabetes
(2–4). We examined the clinical char-
acteristics and HLA associations of
interferon-associated type 1 diabetes.
RESEARCH DESIGN AND
METHODS—We enrolled 12 consec-
utive patients(four men, eightwomen) in
whom type 1 diabetes developed during
or after interferon therapy for chronic
hepatitis C from 1998 to 2009, during
which 1,250 patients with chronic hepa-
titis C were treated with interferon. For
comparison of clinical features, 128 pa-
tients with type 1A diabetes (77 men and
51 women) in whom anti-GAD65 anti-
bodies or fasting serum C-peptide levels
were measured at least once during the 4
years after the onset of type 1 diabetes
were enrolled from previous studies (5).
The number of patients for whom data
wereavailableonGAD65antibodies,fast-
ing serum C peptide, or insulin dosage at
eachdesignatedtimepointispresentedin
Supplementary Table 1. As genetic con-
trols, 10 patients who did not develop di-
abetes and were negative for GAD65
antibodies after interferon therapy for
chronic hepatitis C (eight men and two
women) were enrolled. In addition, 136
normal controls were also enrolled (5).
This study was approved by the institu-
tional ethics committee. All patients gave
informed consent for DNA analysis.
Levels of GAD65 antibodies were
measured using an immunoprecipitation
assay (Cosmic Co., Tokyo, Japan), and
titers of GAD65 antibodies .1.5 units/mL
(mean 1 3 SD of normal controls) were
judgedaspositive.C-peptideassay,typing
of HLA-A, -DRB, -DQA, and -DQB alleles,
and subsequent determination of the
DRB1-DQA1-DQB1 haplotype were per-
formed as previously described (5). As
an index of glycemic control during the
ﬁrst 5 years of the disease, mean A1C (6)
was calculated when onset was later than
1994.
In the case-control study, the odds
ratio (OR) and their 95% CIs were calcu-
lated by logistic regression. The Mann-
Whitney U test was used to compare
unpaired data. Difference of frequency
between the two groups was assessed by
the Fisher exact probability test. Results
are expressed as the means 6 SD except
for titers of GAD65 antibodies, which are
presented as median (range).
RESULTS—Type 1 diabetes occurred
during interferon therapy in seven pa-
tients, within 3 months after interferon
therapy in three patients, and 1 or 5 years
after interferon therapy in two patients.
Of 12 patients with interferon-associated
type1diabetes,10(83.3%)showedketosis
attheonsetand11(91.7%)neededinsulin
therapy within 3 months after the onset of
diabetes.
Titers of GAD65 antibodies as well as
levels of fasting serum C-peptide were
higher in the patients with interferon-
associated type1diabetesthanthose with
type 1A diabetes at onset, 1 year, and 2–4
years after the onset of diabetes (Fig. 1A
and B). The insulin dose required did not
differ between the two groups at onset,
but was lower at 1 year and at 2–4 years
in the patients with interferon-associated
type1diabetes(Fig.1C).MeanA1Clevels
during the ﬁr s t5y e a r sd i dn o td i f f e rb e -
tween the two groups (7.47 6 0.97 [n =
12] vs. 7.88 6 1.38% [n = 41], P = 0.51).
TheHLA-A*2402allelewaspresentin
12 of 24 (50%) of those with interferon-
associated type 1 diabetes compared with
four of 20 (20%) in those without diabe-
tes despite interferon therapy (OR 4.00
[95% CI 1.09–17.26]; P = 0.045;
Supplementary Table 2). Details of inter-
ferontherapydidnotdifferbetweenthese
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Pathophysiology/Complications
BRIEF REPORTFigure 1—Titers of GAD65 antibodies (Abs) (A), fasting serum C-peptide levels (B), and insulin doses (C) in patients with interferon-associated
type 1 diabetes (IFN-T1D) and those with type 1A diabetes (T1AD) at onset, 1 year after onset, and 2–4 years after onset of type 1 diabetes. The
horizontalbars(–––––)inpanelArepresentmedians,exactvaluesofwhichwere3,309vs.7.7units/mLatonset,347vs.1.6units/mLat1yearafter
onset, and 1,247 vs. 3.5 units/mL at 2–4 years after onset. The horizontal bars (–––––)i np a n e l sB and C represent means.
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Interferon-associated type 1 diabetestwo groups (Supplementary Table 3).
Haplotype frequency of DRB1*1302-
DQA1*0102-DQB1*0604 was increased
in these two groups combined (36.4%
[6/44]) compared with normal controls
(9.2% [25/272], P , 0.0001; OR 5.64
[95% CI 2.67–11.81]) and those with
type 1A diabetes (4.9% [10/206], P ,
0.0001;OR11.20[95%CI4.70–27.96]).
CONCLUSIONS—Chronic hepatitis
C is strongly associated with type 2 di-
abetes(7),whereastheoccurrenceoftype
1 diabetes in chronic hepatitis C is almost
alwaysassociatedwiththeuseofinterferon
(2–4). The incidence rate of interferon-
associated type 1 diabetes in chronic hep-
atitis C was 0.96% (12/1,250) in our
institution. Compared with type 1A dia-
betes, interferon-associated type 1 diabe-
tes was characterized by a higher level of
GAD65 antibodies and preserved b-cell
function, which led to a smaller dose of
insulin despite comparable levels of A1C.
However, the acute mode of onset and the
needforsimilardosesofinsulinatonsetin
interferon-associatedtype1diabetescom-
pared with type 1A diabetes may be partly
related to insulin resistance caused by in-
terferon a (8).
Our preliminary examination showed
highlevelsofseruminterleukin(IL)-18and
undetectable serum IL-12 at the onset of
interferon-associated type 1 diabetes (9).
IL-18enhancestheTh2-drivenimmunere-
sponse in the absence of IL-12 (10).
Furthermore, an inverse relationship
exists between humoral and cellular im-
munity to GAD in type 1 diabetes (11).
Thesesituationsmayleadtoahightiterof
GAD antibodies along with relatively pre-
served b-cell function in interferon-
associated type 1 diabetes. On the other
hand, insulinoma-associated antigen-2
antibodies showed no difference in titers
between seven patients with interferon-
associated type 1 diabetes and 12 with
type 1A diabetes (K.N.,unpublished data).
HLA-A*2402, which is implicated in
susceptibility to type 1 diabetes (12,13)
and is related to early complete b-cell de-
struction in type 1 diabetes (5), was asso-
ciated with occurrence of type 1 diabetes
after exposure to interferon. In addition,
the haplotype ofDRB1*1302-DQA1*0102-
DQB1*0604 was associated with chronic
hepatitisCthatrequiredinterferontherapy
regardless of the subsequent occurrence
of type 1 diabetes. DRB1*13 was reported
to be increased in Brazilian patients of
Caucasian origin (14) and Turkish pa-
tients with chronic hepatitis C (15). The
current study cannot determine whether
the DRB1*1302-DQA1*0102-DQB1*0604
haplotype is necessary for susceptibility to
interferon-associatedtype1diabetes.How-
ever, type 1 diabetes occurs more fre-
quently in patients treated for chronic
hepatitis C than for other conditions (2),
which suggests that the addition of
A*2402 to the DRB1*1302-DQA1*0102-
DQB1*0604 haplotype contributes to the
susceptibility to interferon-associated type
1 diabetes. Nonetheless, these HLA associ-
ations, as well as the speciﬁc clinical fea-
tures in interferon-associated type 1
diabetes, need to be conﬁrmed in subse-
quent large-scale studies.
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